Bellerophon Therapeutics (BLPH) Tops Q1 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Bellerophon Reports First Quarter 2016 Financial Results and Provides Business Update
May 10, 2016 6:33 AM EDTWARREN, N.J., May 10, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company, today reported financial results for the first quarter ended March 31, 2016 and provided a business update.
During the first quarter, we advanced our clinical and operational plans, stated Jonathan Peacock, Chairman and Chief Executive Officer of Bellerophon Therapeutics. With receipt of FDA and EMA approval for our global Phase 3 clinical program for INOpulse for the treatment of Pulmonary Arterial Hypertension, or PAH, we look forward to commencing the enrollment of patients in the first of two Phase 3... More
